Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Dysregulation of brain iron homeostasis is central to early neuropathological events in Alzhei mer's disease (AD), including oxidative stress, inflam matory processes, amyloid deposition, tau phosphory lation, and neuronal cell cycle regulatory failure, leading to apoptosis. Also, there is a direct link between iron metabolism and AD pathogenesis, demonstrated by the presence of an iron‐responsive element in the 5′ UTR of the amyloid precursor protein transcript. As a consequence of these findings, a new paradigm is emerging that includes the development of iron‐chelating neuroprotective‐neurorescue drugs with multimo dal functions, acting at various pathological brain tar gets. This concept is challenging the widely held assumption that “silver bullet” agents are superior to “dirty drugs” in drug therapy for neurodegenerative diseases. At best, the so‐called magic bullets exhibit moderate symptomatic activity without modifying the course of disease progression. The present review elaborates on conventional and novel therapeutic tar gets of various multifunctional iron‐chelating drugs ( e.g., chemically designed compounds; natural polyphe nols) that address multiple central nervous system etiologies in AD, aimed at preventing or slowing disease evolution. A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovas cular diseases, and depression.—Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H. Mandel, S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J . 22, 1296–1305 (2008)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The benefits of administration of desferrioxamine in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators”
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Both extracellular amyloid plaques and intracellular NFTs are central pathological hallmarks of AD (33).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801 · cited 1×
“There is increasing evidence that excessive iron accumulation in the brain occurs in many neurodegenerative diseases (1).”
BackgroundSelf-citationCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“burden and slowed the rate of cognitive decline (8).”
BackgroundMitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“drial abnormalities (55); activation of select signal”
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“reduction in plasma amyloid-beta (A ) peptide A (1–42) and cognitive decline in AD patients (7), while in trans-”
BackgroundTargeting Multiple Signaling Pathways by Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate
Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3636 · Cited by 820
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Cited by
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
“In conclusion, considring the multiple iron-operating sites in Alzheimer’s disease, ron chelators, possessing several active neuroprotective moieties an suppress the wide spectrum of oxidative stress-associated europathologies, aswell as amyloidprecursor protein (APP) transation, A generation, and amyloid plaque and n…”
BackgroundTargeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
“This group has incorporated structural features of both rivastigmine and donepezil into a bifunctional chelator HLA20 [5-(4-propargylpiperazin-1-ylmethyl)-8-hydroxyquinol] in which the carbamoyl moiety of rivastigmine acts a protective group to mask the quinolinol oxygen playing an important role in metal chelation [9…”
BackgroundIron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
“3), which can be reversed using iron chelators (Yamamoto et al. 2002; Lovell et al. 2004; Chan and Shea 2006; Amit et al. 2008).”
BackgroundKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases [867] [868] [869] [870] [871] [872] [836] [873] [837] [850] [874] [875] [876] [877] [854] [878] [879] [880] [881] [842] [882] [883] [884] [885] [886] [887] [888] [889] [890] [891] [892] [893] [894] [895] [896] [897]…”
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
Masaldan, S., Bush, A. I., Devos, D., Rolland, A. S., & Moreau, C. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 481
“These events can be mitigated through iron chelation [2,201].”
Metadata
- Authors
- Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Youdim, Moussa B. H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 22
- Issue
- 5
- Pages
- 1296-1305
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2072788211
- Cited by
- 126
- References
- 89
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 9 · 2012: 12
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Alzheimer's disease, iron chelators, brain iron homeostasis, neuroprotection, neurorestoration, oxidative stress, neuroinflammation, amyloid deposition, tau phosphorylation, neuronal apoptosis, iron-responsive element, amyloid precursor protein, polyphenols, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Brain, Catechin, Cell Cycle, Humans, Hydroxyquinolines, Iron, Iron Chelating Agents, Piperazines, Amyloid beta-Protein Precursor, PC12 Cells, Neuroprotective Agents, Neurodegenerative Diseases, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.